Corporate ActionAug 6, 2026, 05:19 PM
Aclaris Therapeutics Amends ATM Agreement for Common Stock Sales
AI Summary
Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. on August 6, 2026. This agreement allows the company to offer and sell common stock through an "at-the-market" offering. It amends and restates a previous agreement from February 27, 2025, which permitted the sale of up to $100.0 million in common stock. The company will pay a 3.0% commission on gross sales proceeds for any shares sold.
Key Highlights
- Entered Second Amended and Restated Sales Agreement on August 6, 2026.
- Allows "at-the-market" offering of common stock through Leerink Partners and Cantor Fitzgerald.
- Amends previous agreement dated February 27, 2025.
- Previous agreement permitted sale of up to $100.0 million in common stock.
- Company to pay 3.0% commission on gross sales proceeds.
- Sales will be made pursuant to a registration statement on Form S-3.
Price Impact
More from ACRS